- Home
- NMRA vs AVIR Comparison
NMRA vs AVIR Comparison
Compare NMRA & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRA
- AVIR
- Stock Information
- Founded
- NMRA 2019
- AVIR 2012
- Country
- NMRA United States
- AVIR United States
- Employees
- NMRA N/A
- AVIR N/A
- Industry
- NMRA
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- NMRA
- AVIR Health Care
- Exchange
- NMRA Nasdaq
- AVIR Nasdaq
- Market Cap
- NMRA 268.5M
- AVIR 290.4M
- IPO Year
- NMRA 2023
- AVIR 2020
- Fundamental
- Price
- NMRA $1.57
- AVIR $2.97
- Analyst Decision
- NMRA Hold
- AVIR Hold
- Analyst Count
- NMRA 8
- AVIR 1
- Target Price
- NMRA $5.83
- AVIR $6.00
- AVG Volume (30 Days)
- NMRA 376.3K
- AVIR 223.7K
- Earning Date
- NMRA 11-11-2025
- AVIR 11-06-2025
- Dividend Yield
- NMRA N/A
- AVIR N/A
- EPS Growth
- NMRA N/A
- AVIR N/A
- EPS
- NMRA N/A
- AVIR N/A
- Revenue
- NMRA N/A
- AVIR N/A
- Revenue This Year
- NMRA N/A
- AVIR N/A
- Revenue Next Year
- NMRA N/A
- AVIR N/A
- P/E Ratio
- NMRA N/A
- AVIR N/A
- Revenue Growth
- NMRA N/A
- AVIR N/A
- 52 Week Low
- NMRA $0.61
- AVIR $2.46
- 52 Week High
- NMRA $17.19
- AVIR $4.10
- Technical
- Relative Strength Index (RSI)
- NMRA 46.94
- AVIR 33.48
- Support Level
- NMRA $1.42
- AVIR $2.84
- Resistance Level
- NMRA $1.59
- AVIR $3.33
- Average True Range (ATR)
- NMRA 0.10
- AVIR 0.14
- MACD
- NMRA -0.03
- AVIR -0.04
- Stochastic Oscillator
- NMRA 36.14
- AVIR 18.98
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).